Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 10

Pharmacogenomics and Personalized Medicine


Archive: Volume 10, 2017

Ethiopian health care professionals’ knowledge, attitude, and interests toward pharmacogenomics

Abdela OA, Bhagavathula AS, Gebreyohannes EA, Tegegn HG

Pharmacogenomics and Personalized Medicine 2017, 10:279-285

Published Date: 5 December 2017

Pharmacogenomics of sickle cell disease: steps toward personalized medicine

Husain M, Hartman AD, Desai P

Pharmacogenomics and Personalized Medicine 2017, 10:261-265

Published Date: 19 October 2017

Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients

Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA

Pharmacogenomics and Personalized Medicine 2017, 10:253-259

Published Date: 27 September 2017

Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?

Rytkin E, Mirzaev KB, Grishina EA, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Giliarov MI, Andreev DA, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:243-245

Published Date: 18 September 2017

ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine

Piatkov I, Caetano D, Assur Y, Lau SL, Jones T, Boyages SC, McLean M

Pharmacogenomics and Personalized Medicine 2017, 10:235-242

Published Date: 28 August 2017

Updating the landscape of direct-to-consumer pharmacogenomic testing

Filipski KK, Murphy JD, Helzlsouer KJ

Pharmacogenomics and Personalized Medicine 2017, 10:229-232

Published Date: 22 August 2017

CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications

St Sauver JL, Olson JE, Roger VL, Nicholson WT, Black III JL, Takahashi PY, Caraballo PJ, Bell EJ, Jacobson DJ, Larson NB, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:217-227

Published Date: 24 July 2017

Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder

Zastrozhin MS, Brodyansky VM, Skryabin VY, Grishina EA, Ivashchenko DV, Ryzhikova KA, Savchenko LM, Kibitov AO, Bryun EA, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:209-215

Published Date: 7 July 2017

Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele

Panagopoulos P, Maltezos E, Hatzakis A, Paraskevis D

Pharmacogenomics and Personalized Medicine 2017, 10:205-208

Published Date: 20 June 2017

Observational study to calculate addictive risk to opioids: a validation study of a predictive algorithm to evaluate opioid use disorder

Brenton A, Richeimer S, Sharma M, Lee C, Kantorovich S, Blanchard J, Meshkin B

Pharmacogenomics and Personalized Medicine 2017, 10:187-195

Published Date: 18 May 2017

CYP2C19*2 status in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis

Laska AJ, Han MJ, Lospinoso JA, Brown PJ, Beachkofsky TM

Pharmacogenomics and Personalized Medicine 2017, 10:183-186

Published Date: 17 May 2017

DNA methylation at the mu-1 opioid receptor gene (OPRM1) promoter predicts preoperative, acute, and chronic postsurgical pain after spine fusion

Chidambaran V, Zhang X, Martin LJ, Ding L, Weirauch MT, Geisler K, Stubbeman BL, Sadhasivam S, Ji H

Pharmacogenomics and Personalized Medicine 2017, 10:157-168

Published Date: 9 May 2017

ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches

Cleophas MC, Joosten LA, Stamp LK, Dalbeth N, Woodward OM, Merriman TR

Pharmacogenomics and Personalized Medicine 2017, 10:129-142

Published Date: 20 April 2017

CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome

Mirzaev KB, Zelenskaya EM, Barbarash OL, Ganyukov VI, Apartsin KA, Saraeva NO, Nikolaev KY, Ryzhikova KA, Lifshits GI, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:107-114

Published Date: 12 April 2017

Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients

Salgado PC, Genvigir FDV, Felipe CR, Tedesco-Silva Jr H, Medina-Pestana JO, Doi SQ, Hirata MH, Hirata RDC

Pharmacogenomics and Personalized Medicine 2017, 10:101-106

Published Date: 31 March 2017

Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations

Sychev DA, Shuev GN, Suleymanov SS, Ryzhikova KA, Mirzaev KB, Grishina EA, Snalina NE, Sozaeva ZA, Grabuzdov AM, Matsneva IA

Pharmacogenomics and Personalized Medicine 2017, 10:93-99

Published Date: 31 March 2017

MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy

Umerez M, Gutierrez-Camino Á, Muñoz-Maldonado C, Martin-Guerrero I, Garcia-Orad A

Pharmacogenomics and Personalized Medicine 2017, 10:69-78

Published Date: 27 March 2017

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment

Takano M, Sugiyama T

Pharmacogenomics and Personalized Medicine 2017, 10:61-68

Published Date: 28 February 2017

Is there evidence that we should screen the general population for Lynch syndrome with genetic testing? A systematic review

Prince AER, Cadigan RJ, Henderson GE, Evans JP, Adams M, Coker-Schwimmer E, Penn DC, Van Riper M, Corbie-Smith G, Jonas DE

Pharmacogenomics and Personalized Medicine 2017, 10:49-60

Published Date: 20 February 2017

Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6

Takahashi PY, Ryu E, Pathak J, Jenkins GD, Batzler A, Hathcock MA, Black JL, Olson JE, Cerhan JR, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:39-47

Published Date: 14 February 2017

The HLA-A*31:01 allele: influence on carbamazepine treatment

Yip VLM, Pirmohamed M

Pharmacogenomics and Personalized Medicine 2017, 10:29-38

Published Date: 31 January 2017

Prevalence of clinically actionable genotypes and medication exposure of older adults in the community

Daneshi N, Holliday E, Hancock S, Schneider JJ, Scott RJ, Attia J, Milward EA

Pharmacogenomics and Personalized Medicine 2017, 10:17-27

Published Date: 27 January 2017

Diet and lifestyle factors associated with miRNA expression in colorectal tissue

Slattery ML, Herrick JS, Mullany LE, Stevens JR, Wolff RK

Pharmacogenomics and Personalized Medicine 2017, 10:1-16

Published Date: 20 December 2016